|
News updates.
JANUARY 5, 2006
Endocyte Signs Agreement with Bristol-Myers Squibb to Develop and Commercialize Folate-Targeted Chemotherapeutic Agents
|
Endocyte has licensed to BMS Endocyte's vitamin-targeting technology to target Bristol-Myers Squibb's proprietary epothilone cancer chemotherapeutic agents. The license is a result of an ongoing collaborative research effort between the two companies to create novel folate conjugates of BMS's proprietary epothilone compounds. BMS is responsible for all development, manufacturing, registration and marketing of the resulting products.
“Bristol-Myers Squibb has been a terrific partner to work with throughout this collaboration,” said Christopher P. Leamon, Ph.D., Vice President of Research at Endocyte, Inc. “Our goal was to construct a tumor-targeted analog of a very potent drug, one that would preserve efficacy but also reduce the opportunity for negative side effects. We were successful because of the high level of commitment, teamwork and excellence provided by the scientists at both companies.” The Endocyte-Bristol-Myers Squibb conjugates will be tumor-targeting drugs and are anticipated to spare healthy cells from the toxic effects of chemotherapy.
DECEMBER 9, 2005
Ambit Expands Collaboration With Bristol-Myers Squibb Company, In-Licenses Kinase Inhibitor Program Targeting Solid Tumors
|
The companies expanded their collaboration for the discovery of kinase inhibitors. The agreement provides Bristol-Myers Squibb with access to Ambit's proprietary kinase profiling technology, KinomeScan, to accelerate its internal drug discovery and development efforts. As part of the collaboration, Bristol-Myers Squibb granted Ambit an exclusive license to develop product candidates from a solid tumor-directed preclinical kinase inhibitor program. In addition, Ambit will receive an upfront payment, an equity investment and profiling service fees.
“The preclinical kinase inhibitor program from Bristol-Myers Squibb complements Ambit's own internal pipeline of kinase inhibitors for the treatment of cancer.” said Scott Salka, CEO of Ambit. “Ambit's kinase profiling technology, KinomeScan, adds significant value by enhancing and expediting the drug discovery and development process, from library and early discovery screening through preclinical and clinical development. The additional unique ability of KinomeScan to rapidly characterize entire libraries of compounds across a panel of well over 200 kinases allows the application of chemogenomics and provides broad insight that cannot be obtained from profiling individual compounds or libraries using conventional enzyme activity assays.”
DECEMBER 6, 2005
Exelixis And Bristol-Myers Squibb Sign New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments
|
Exelixis and BMS signed a collaboration agreement to discover, develop and commercialize novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor implicated in a variety of cardiovascular and metabolic disorders.
The companies will jointly identify drug candidates that are ready for Investigational New Drug Application enabling studies. Bristol-Myers Squibb will undertake further preclinical development and would be responsible for clinical development, regulatory, manufacturing and sales/marketing activities for such compounds.
“We are very excited about combining the strengths of our two organizations. We have worked together productively in the past and we look forward to successfully combining our expertise in drug discovery and early biology with the proven capabilities of Bristol-Myers-Squibb in developing and commercializing important therapies for cardiovascular disease,” said George A. Scangos, Ph.D., president and chief executive officer of Exelixis.
“This collaboration is strongly aligned with Bristol-Myers Squibb's strategy of focusing on therapies addressing areas of serious medical need,” said Francis Cuss, M.D., senior vice president of Drug Discovery for Bristol-Myers Squibb. “We believe that LXR agonists, by triggering reverse cholesterol transport and reducing inflammation in vessel walls, have significant potential to treat atherosclerosis and cardiovascular disease. We look forward to combining our efforts with scientists from Exelixis to bring this new class of medicines into clinical testing.”
OCTOBER 24, 2005
Albany Molecular Research, Inc. and Bristol-Myers Squibb enter into licensing agreement for neuroscience compounds
The two companies will collaborate to discover and develop compounds to treat depression and other central nervous system disorders. Albany has licensed multiple compounds to Bristol-Myers Squibb and will continue to provide research support to further characterize those compounds and identify additional compounds. Bristol-Myers Squibb will provide preclinical, clinical and commercial expertise, and will be responsible for development, registration and marketing worldwide.
"We are thrilled to be working with Bristol-Myers Squibb on the further development of these compounds," said CEO and president Thomas E. D'Ambra, PhD. "We are excited by the commercial potential for these compounds and believe there is a possibility that our combined efforts could yield multiple drugs with a range of different profiles. Bristol-Myers Squibb is an ideal company for our technology, and we look forward to a productive and mutually rewarding collaboration."
DECEMBER 22, 2004
Bristol-Myers Squibb and Somerset Pharmaceuticals enter into agreement to develop and commercialize EMSAM®, an investigational transdermal treatment for Major Depressive Disorder
The two companies have entered into an agreement for the commercialization and distribution of Somerset's EMSAM® (selegiline transdermal system), an investigational monoamine oxidase inhibitor administered as a transdermal patch for the acute and maintenance treatment of patients with major depressive disorder.
“We are excited to announce that we have partnered on EMSAM® with Bristol-Myers Squibb, which has a strong record in neuroscience,” said Mel Sharoky, M.D., Somerset's president and chief executive officer. “This agreement with Somerset Pharmaceuticals marks a continued step forward in our efforts to deliver new and effective treatments to people with psychiatric disorders,” said Anthony Hooper, president, U.S. Pharmaceuticals, Bristol-Myers Squibb.
DECEMBER 20, 2004
Bristol-Myers Squibb and Gilead Sciences establish U.S. Joint Venture to develop and commercialize fixed-dose combination of three HIV medicines
|
The two companies have established a joint venture to develop and commercialize the fixed-dose combination of Bristol-Myers Squibb's Sustiva® (efavirenz) www.sustiva.com and Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) in the United States. If approved, the new product would be the first complete Highly Active Antiretroviral Therapy (HAART) treatment regimen for HIV available in a fixed-dose combination taken once daily.
“This landmark partnership reflects the dedication Gilead and Bristol-Myers Squibb bring to delivering simplified therapy to physicians and patients. We look forward to working with the Bristol-Myers Squibb team to ensure this novel therapeutic advancement reaches physicians and people living with HIV/AIDS as rapidly as possible,” commented John C. Martin, PhD, president and chief executive officer, Gilead Sciences.
“We are pleased to be leveraging our leadership in HIV through this collaboration with Gilead to help advance the management of the disease through the development of potentially more convenient treatment options," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb Company.
NOVEMBER 8, 2004
Medarex and Bristol-Myers Squibb enter into global agreement to develop and commercialize novel antibody product to treat melanoma
|
The two companies will co-develop an investigational fully human antibody product currently in Phase III clinical trials for the potential treatment of metastatic melanoma and in Phase II clinical trials for the potential treatment of other solid tumors. Once commercialized, Medarex will have the option to co-promote with BMS in the United States.
In joining forces, the partnership will fully leverage each company's expertise. “We are enthusiastic about joining forces with Bristol-Myers Squibb, an outstanding company with a world class oncology business,” said Donald L. Drakeman, president and chief executive officer of Medarex, Inc. “We look forward to our partnership with Medarex, a leader in antibody development, and hope that we might further extend and enhance the lives of cancer patients.” said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb.
MAY 17, 2004
Solvay Pharmaceuticals and Bristol-Myers Squibb in joint development and future commercialization of novel obesity compound.
The two companies are working together on Solvay’s Phase I compound SLV319, which has potential use in treating obesity and other metabolic disorders. The partnership leverages Bristol-Myers Squibb’s established leadership position in metabolics, and the company’s ability to increase the speed of the development process.
Solvay Pharmaceuticals selected Bristol-Myers Squibb as a partner not only for expertise, but for the human part of the equation, as well. "Enthusiasm is important," notes Werner Cautreels, Solvay’s senior vice president and worldwide head of research and development. "And certainly something that Bristol-Myers Squibb did not have was the well-known NIH -- or "not invented here" -- syndrome." Finally, he noted, "In a relationship like this, it’s not only the quality of the compound and the quality of the work that’s important, but also the quality of the people working together."
APRIL 10, 2004
Pierre Fabre Médicament S.A. and Bristol-Myers Squibb enter into agreement to develop and commercialize oncology treatment
The two companies have entered into an agreement to develop and commercialize an investigational compound currently in Phase III clinical trials for the potential treatment of bladder and non-small cell lung cancer, and Phase II clinical trials for the potential treatment of breast and ovarian cancer.
The partnership is seen as a winning combination by both companies. "We are particularly satisfied to be partnering with a premier oncology company like Bristol-Myers Squibb. The collaboration underlines the expertise of our group's research department in the area of oncology, our main research area," said Dr. Jean-Pierre Couzinier, Pierre Fabre Médicament Chief Operating Officer. "We look forward to teaming up with a pioneering company such as the Pierre Fabre Group," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb.
DECEMBER 18, 2003
Lexicon Genetics and Bristol-Myers Squibb form neuroscience alliance for drug development.
|
The neuroscience alliance aims to accelerate the discovery and development of breakthrough therapies to address unmet medical needs in such disease areas as depression, anxiety, schizophrenia, pain, and Alzheimer's disease. Lexicon is contributing drug discovery targets from its current neuroscience pipeline, and is providing the alliance exclusive access to future novel targets in neuroscience discovered in its Genome5000 program. Bristol-Myers Squibb will provide the clinical and commercial expertise to bring new products to patients worldwide.
The combination is powerful. Bristol-Myers Squibb and Lexicon will launch a joint medicinal chemistry and preclinical effort to discover small molecule compounds that bind to these novel targets and advance those compounds into clinical trials. As compounds enter the clinical stage, Bristol-Myers Squibb has the first option to take them through development and into commercialization. In return, Lexicon will receive milestones and royalty payments. Lexicon and Bristol-Myers Squibb will work together to discover and develop drugs that act through these novel investigational targets for patients who are affected with psychiatric and neurological disorders.
DECEMBER 18, 2003:
Bioentrepreneur, "Biotechs critique big pharma's collaboration skills."
Bristol-Myers Squibb named the best at collaborating with biotech companies.
According to a survey of CEOs and business development directors of biotechnology companies in the United States, United Kingdom, and Germany, Bristol-Myers Squibb is the best at collaboration with biotech companies. The survey measured perceptions of how pharmaceutical companies performed on criteria that are essential to successful partnerships. Criteria included a high level of empathy with the partner's objectives, flexibility in deal structure, ability to move quickly, direct access to key decision makers, and sticking to the sentiment of the agreement throughout the lifetime of the alliance.
|
